All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Results from the phase III INO-VATE (NCT01564784) trial evaluating the efficacy of inotuzumab ozogamicin (InO) for the treatment of relapsed/refractory acute lymphoblastic leukemia (R/R ALL) were published in Blood Advances by Zhao et al.1 Responses to InO were recorded in 91 patients by leukemic subtype, genomic alterations, and risk status.
|
Key learnings |
The median overall survival was 7.7 months with InO compared with 6.2 months with standard of care (SoC) chemotherapy (hazard ratio, 0.75; p = 0.0105). |
Patients with high-risk molecular profiles experienced improved complete remission (CR) and CR with incomplete hematologic recovery (CRi) rates with InO compared with SoC chemotherapy (74.7% vs 33.3%; p < 0.001).
|
The CR rate in patients with TP53 alterations was also higher with InO compared with SoC chemotherapy (100% vs 12.5%; p = 0.0047). |
The findings from the study suggest that InO may be a viable option for patients with R/R ALL, particularly those with high-risk molecular profiles, offering personalized treatment strategies. Further exploration of InO efficacy is needed in patients with BCR::ABL1-like subtype and TP53 alterations.
|
Your opinion matters
Subscribe to get the best content related to ALL delivered to your inbox